Jardiance (Empagliflozin) 25 mg 30 Film-Coated Tablets

Jardiance (Empagliflozin) 25 mg 30 Film-Coated Tablets is a branded SGLT‑2 inhibitor used to improve blood glucose control in adults (and children aged 10+) with type 2 diabetes. It also reduces the risk of cardiovascular death, hospitalization for heart failure, and progression of chronic kidney disease.

Key Benefits of Jardiance (Empagliflozin) 25 mg 30 Film-Coated Tablets:

1. Lowers HbA1c by ~0.7–0.8% and fasting glucose by ~19–25 mg/dL.
2. Promotes moderate weight loss (~2–3%) and reduces systolic blood pressure by 3–5 mmHg.
3. Provides cardiovascular and renal protection independently of glycemic control.

Mechanism of Action:

Blocks renal SGLT‑2, reducing glucose reabsorption and increasing urinary glucose excretion leading to lower blood sugar and mild diuresis.

Dosage & Administration:

1. Typical dose: 1 tablet (25 mg) once daily in the morning, with or without food.
2. Initial dose: Often starts at 10 mg, can be uptitrated to 25 mg for better glycemic control.
3. Missed dose: Skip if near your next scheduled dose; do not double dose.

Warnings & Contraindications:

1. Not for type 1 diabetes, diabetic ketoacidosis, or eGFR < 30 mL/min/1.73 m².
2. Risk of dehydration, hypotension, and genital yeast infections.
3. Serious but rare: euglycemic ketoacidosis, Fournier’s gangrene, acute kidney injury.

Common Side Effects:

1. Genital mycotic infections, UTIs, increased urination, mild hypotension, thirst, nausea, headache.

Serious Side Effects:

1. Euglycemic ketoacidosis (nausea, vomiting, stomach pain, breathing changes).
2. Fournier’s gangrene, acute kidney injury, significant hypotension/hyponatremia.

Warnings & Patient Advice:

Ensure adequate hydration, monitor blood pressure and kidney function. Discontinue 3 days before surgeries or if unwell. Avoid in pregnancy and breastfeeding without medical guidance

Prescription Medication, SGLT‑2 Inhibitor, Antidiabetic, Empagliflozin, Type 2 Diabetes, Heart Failure, Renal Protection